Published in Cancer on August 15, 1983
Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer (2009) 1.14
An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. Br J Cancer (1990) 1.07
Biochemical prediction of response of bone metastases to treatment. Br J Cancer (1988) 1.07
3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer. Br J Cancer (1987) 1.06
Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer (1996) 1.03
18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res (2011) 1.03
Imaging response to systemic therapy for bone metastases. Eur Radiol (2009) 0.99
Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. Br J Cancer (1992) 0.96
Histological grade and steroid receptor content of primary breast cancer--impact on prognosis and possible modes of action. Br J Cancer (1988) 0.86
Breast cancer, prostaglandins and patient survival. Br J Cancer (1989) 0.84
SEOM Clinical Guideline for bone metastases from solid tumours (2016). Clin Transl Oncol (2016) 0.79
Lytic bone metastases after APD in breast carcinoma. BMJ (1988) 0.75
Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet (1994) 4.03
Bone disease after jejuno-ileal bypass for obesity. Lancet (1978) 3.84
Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet (1980) 2.82
The use of antisera to epithelial membrane antigen in detecting micrometastases in histological sections. Br J Cancer (1980) 2.50
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol (1993) 2.50
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Plasma-immunoreactive-calcitonin in patients with non-thyroid tumours. Lancet (1974) 2.30
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol (1998) 2.18
Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res (2001) 2.15
Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer (1992) 2.10
Association between patient and general practice characteristics and unplanned first-time admissions for cancer: observational study. Br J Cancer (2012) 2.10
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet (1987) 2.09
Detection of micrometastases in patients with primary breast cancer. Lancet (1983) 2.07
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res (1987) 2.03
Mammography and breast cancer. N Z Med J (1990) 2.01
Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet (1976) 1.92
Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet (1980) 1.88
Radiation-induced brachial plexus injury: follow-up of two different fractionation schedules. Radiother Oncol (1990) 1.86
Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res (1994) 1.84
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy (1999) 1.83
The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. Br J Cancer (1973) 1.81
Survey of treatment of primary breast cancer in Great Britain. Br Med J (Clin Res Ed) (1985) 1.80
Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia (2000) 1.79
Vitamin D status and bone histomorphometry in gross obesity. Am J Clin Nutr (1981) 1.79
Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell (2000) 1.77
Grey scale echography in the diagnosis of intrahepatic disease. J Clin Ultrasound (1973) 1.71
Diagnosing breast carcinoma in young women. BMJ (1991) 1.71
Ultrasound and scintigraphy in the differential diagnosis of obstructive jaundice. J Clin Ultrasound (1974) 1.70
Recurrent Cancer of Head and Neck. Br Med J (1962) 1.63
Tamoxifen for the prevention of breast cancer. Eur J Cancer (2000) 1.62
Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol (1999) 1.60
FDG accumulation and tumor biology. Nucl Med Biol (1998) 1.59
Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol (2005) 1.59
Effect of antilymphocyte serum on the growth of Hep 2 and HeLa cells in mice. Nature (1968) 1.58
Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A (2001) 1.55
Treatment of gross obesity by jejunal bypass. Br Med J (1974) 1.55
Injury and anomie: effects of violence on an inner-city community. Am J Public Health (1998) 1.54
Topical calcipotriol treatment in advanced breast cancer. Lancet (1991) 1.53
Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy. Ann Oncol (1999) 1.51
Estrogen and progesterone receptors in the normal female breast. Cancer Res (1991) 1.50
The potential of intratumoural unsealed radioactive source therapy. Eur J Nucl Med (2001) 1.49
Biochemical markers in human breast cancer. Lancet (1977) 1.48
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol (1987) 1.47
c-erbB-2 expression in benign and malignant breast disease. Br J Cancer (1988) 1.47
Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet (1987) 1.46
Future directions for unsealed source radionuclide therapy for bone metastases. Eur J Nucl Med Mol Imaging (2002) 1.45
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer (2000) 1.45
Clinical examination, xeromammography, and fine-needle aspiration cytology in diagnosis of breast tumours. Br Med J (1978) 1.44
Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J Biol Chem (1997) 1.42
Physical test for distant metastases in patients with breast cancer. J R Soc Med (1980) 1.42
Estrogen receptor beta in breast cancer. Endocr Relat Cancer (2002) 1.41
Reversal of jejunoileal bypass in patients with morbid obesity. Br J Surg (1994) 1.39
Pharmac--what next? N Z Med J (1998) 1.39
Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer (1981) 1.39
Technique for abdominal radical total gastrectomy. Br J Surg (1989) 1.39
Prevention of breast cancer. Curr Opin Oncol (1991) 1.39
Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J Clin Oncol (1986) 1.39
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet (1980) 1.38
Explanations for weight loss after ileojejunal bypass in gross obesity. Br Med J (1976) 1.37
Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J (Clin Res Ed) (1987) 1.36